CrystalGenomics Submits IND for Phase 2 Clinical Trial Targeting Pancreatic Cancer Patients to US FDA
[Asia Economy Reporter Minji Lee] CrystalGenomics announced on the 20th that it has submitted a clinical phase 2 trial plan to the US FDA to compare the efficacy and safety of ivaltinostat/capecitabine combination therapy and capecitabine monotherapy in patients with metastatic pancreatic cancer.
Hot Picks Today
!["It Has Finally Crossed Borders"... Greater Fear Due to Delayed Detection, No Treatment for Variant Ebola [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/93/2026052019230771274_1779272587.jpg)
"It Has Finally Crossed Borders"... Greater Fear Due to Delayed Detection, No Treatment for Variant Ebola [Reading Science]
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated, "By administering capecitabine, which is used as maintenance therapy for pancreatic cancer, in combination with ivaltinostat, an anticancer drug candidate with confirmed tolerability and safety, we expect a significantly enhanced anticancer effect," adding, "We believe we can offer better treatment options to pancreatic cancer patients."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
